Foghorn Therapeutics (FHTX) Tax Provisions (2023)
Foghorn Therapeutics (FHTX) posted quarterly Tax Provisions of $2.0 million for Q4 2023, up 169.11% quarter-over-quarter from $738000.0 in Q3 2023.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Tax Provisions (2023) Analysis & Trends
Foghorn Therapeutics' Tax Provisions history runs 1 years deep, the most recent figure standing at $2.0 million for Q4 2023.
- In Q4 2023, Tax Provisions changed N/A year-over-year to $2.0 million; the TTM figure through Sep 2024 stood at $2.0 million (down 11.34% YoY), while the FY2023 annual figure was $4.2 million, changed N/A from the prior year.
- Tax Provisions for Q4 2023 stood at $2.0 million, up from $738000.0 in the prior quarter.
- The five-year high for Tax Provisions was $2.0 million in Q4 2023, with the low at $560000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Foghorn Therapeutics | 346.08 Mn | 278.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 1.99 Mn |
| Sep 30, 2023 | 738,000.00 |
| Jun 30, 2023 | 942,000.00 |
| Mar 31, 2023 | 560,000.00 |